Amgen (a biotechnology company) immediately began setting up clinical trials to determine whether the neuroprotective properties of GDNF would translate into humans, sensing that they were on to a potentially blockbuster cure for Parkinson’s. This evidence concerns the gene GDNF and Parkinson disease.